# Lung Cancer Research Studies
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/lung-cancer-research-studies/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers represents a comprehensive exploration of small cell lung cancer, covering topics such as genomic profiles, immunotherapy, chemotherapy, prognostic factors, biomarkers, targeted therapy, clinical trials, metastasis, and tumor markers. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12334 |
| Works | 879 |
## Topic papers all
Showing 15 of 879.
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma](https://scholariq.org/papers/gefitinib-or-carboplatin-paclitaxel-in-pulmonary-adenocarcinoma/)
- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Erlotinib in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/erlotinib-in-previously-treated-non-small-cell-lung-cancer/)
- [Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States](https://scholariq.org/papers/one-hundred-years-after-carcinoid-epidemiology-of-and-prognostic-factors-for/)
- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/)
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States](https://scholariq.org/papers/trends-in-the-incidence-prevalence-and-survival-outcomes-in-patients-with/)
- [Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Lung cancer: current therapies and new targeted treatments](https://scholariq.org/papers/lung-cancer-current-therapies-and-new-targeted-treatments/)
- [Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
## Topic primary papers
Showing 15 of 163.
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Comprehensive genomic profiles of small cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-profiles-of-small-cell-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database](https://scholariq.org/papers/changing-epidemiology-of-small-cell-lung-cancer-in-the-united-states-over-the/)
- [Small-cell lung cancer](https://scholariq.org/papers/small-cell-lung-cancer/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://scholariq.org/papers/molecular-subtypes-of-small-cell-lung-cancer-a-synthesis-of-human-and-mouse/)
- [Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-analysis-identifies-sox2-as-a-frequently-amplified-gene-in/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer](https://scholariq.org/papers/rb-loss-in-resistant-egfr-mutant-lung-adenocarcinomas-that-transform-to-small/)
- [Small cell lung cancer: Where do we go from here?](https://scholariq.org/papers/small-cell-lung-cancer-where-do-we-go-from-here/)
- [Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-anlotinib-as-a-third-line-or-further-treatment-on-overall-survival-of/)
- [Malignant small cell tumor of the thoracopulmonary region in childhood.A distinctive clinicopathologic entity of uncertain histogenesis](https://scholariq.org/papers/malignant-small-cell-tumor-of-the-thoracopulmonary-region-in-childhood-a/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.